
|Videos|December 22, 2015
Dr. Peter Beitsch on Pertuzumab in the Luminal Subtype of HER2-Positive Breast Cancer
Author(s)Peter Beitsch, MD
Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses a triplet of chemotherapy, trastuzumab, and pertuzumab in the adjuvant and neoadjuvant settings.
Advertisement
Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses a triplet of chemotherapy, trastuzumab, and pertuzumab in the adjuvant and neoadjuvant settings. Beitsch argues that pertuzumab should be included in the triplet due to its prolonging survival in patients with HER2-positive breast cancer that have the 80-gene Luminal subtype.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































